Background: The Erythropoietin in Traumatic Brain Injury (EPO-TBI) trial aims to determine whether the administration of erythropoietin to patients with moderate or severe traumatic brain injury improves patient-centred outcomes.
Introduction
Traumatic brain injury (TBI) is a leading cause of mortality and long-term disability, particularly affecting young people. Even a small increase in the number of TBI victims who are able to live independently, instead of being permanently disabled, would yield major human and economic gains [1, 2] .
Erythropoietin (EPO) has shown promise as an agent to attenuate TBI, as EPO appears to have neuroprotective effects as well as its better known effect on erythropoiesis [3] . EPO-TBI is an international multicentre, blinded, randomised, parallel groups, placebo-controlled, phase III superiority trial of erythropoietin administration to adult ICU patients with acute TBI of at least moderate severity [4, 5] .
The trial is being conducted, and accumulating data monitored, according to the standard requirements of Good Clinical Practice [6] . Ethics and regulatory approvals of the protocol and related documents were obtained prior to commencing the trial at each site according to state or national legislation. The list of responsible ethics committees is provided in Additional file 1.
Informed consent was obtained from each patient's legal surrogate for participation in the trial. Patients who recover sufficient cognition to understand the explanation of the trial will additionally be asked to consent to continue in the trial if this is required under the ethics committee approval conditions. In France patients may be enrolled under the Emergency clause. More details of the trial protocol and participating hospitals are available from the trial registration site [7] as well as from a forthcoming manuscript (Nichol and colleagues, manuscript submitted).
General confidence in the final results and conclusions of clinical trials is enhanced when the statistical approaches to outcome analyses are specified prior to the availability of trial data. The following statistical analysis plan complies with recommendations for the Consolidated Standards of Reporting Trials [8] as well as guidance from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, especially "Statistical principles for clinical trials E9" [9] and "Structure and content of clinical study reports E3" [10] .
This statistical analysis plan identifies the procedures to be applied to the primary and secondary outcome analyses in the whole trial cohort once trial data validation is complete. Covariates for adjusted analyses and selected subgroups of interest are also pre-specified.
Methods

Study design and definitions
EPO-TBI is a multicentre, prospective, two parallel groups, blinded, placebo-controlled, randomised phase III superiority trial of erythropoietin administration to adult ICU patients with TBI of at least moderate severity. The primary objective of this trial is to demonstrate that longterm neurological function assessed 6 months after injury is improved following early administration of EPO compared to a placebo control. Exploratory secondary and adjusted multivariable analyses will also be conducted.
Trial population and eligibility
A total of 606 TBI patients will be enrolled in Australia, New Zealand, Saudi Arabia, France, Finland, Germany, and Ireland. There are 29 individual research sites defined by the hospital treating each patient, with investigators representing a team of clinicians recruiting patients at one or several related hospitals. The inclusion and exclusion criteria are presented in Table 1 . Eligible patients will be randomised to receive by subcutaneous injection either erythropoietin (Epoetin alfa, Jansen-Cilag Pty Ltd; 40,000 IU in 1 mL from a pre-filled syringe) or an equal volume placebo comprising 0.9% sodium chloride. The study drug or placebo will be administered once per week for up to three doses provided the patient continues to require ICU care and meets no drug-withholding criteria. Measurements of treatment compliance will consist of summaries of the count of EPO/placebo doses received.
Randomisation
Trial treatment is allocated between EPO and placebo in a ratio of 1:1 via a confidential internet-based 24 hour centralised computer-generated randomisation schedule which provides concealed immediate assignment. Balance in treatment allocation across the study participants will be enhanced through stratification by both research site (defined by each participating hospital) as well as by each patient's initial pre-intubation Glasgow Coma Score (GCS); with a score of 9 to 12 indicating moderate, and a GCS of 3 to 8 indicating severe TBI. Randomisation within these strata will follow a permuted block scheme to further enhanced treatment balance.
Treatment masking (blinding)
The trial will be conducted as a blinded trial. Patients, site investigators, site research coordinators, the French management team, staff at the Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), central outcome assessors (Appendix 1), and the statisticians for interim and final analyses will not be advised of treatment allocation.
For the efficient conduct of the trial several staff will be unblinded. They are the research site pharmacist, the central pharmacy in France (Clinical Trial Department of the Pharmaceutical Establishment of Assistance Publique-Hôpitaux de Paris), the ANZIC-RC unblinded project officer (Appendix 2), a nominated statistician who will supervise data extraction from the database for interim and final analyses, and the Monash University Clinical Informatics and Data Management Unit [11] staff who administer the internet-based computerised randomisation process. Also, for reasons of safety, unblinded dosing nurses will be allocated in each research site to administer EPO or placebo doses discreetly with a screen around the patient bed area. The trial drug/placebo dose may be checked with a second unblinded nurse if required to comply with local hospital regulations. These unblinded dosing nurses have access to the unblinded trial pharmacist. Unblinded dosing nurses will not be involved in the care of a trial patient and may not discuss study drug treatment with research staff or other members of the ICU or hospital staff.
When final database entries have been made and final queries have been resolved, the EPO-TBI research database will be locked. Application of this trial statistical analysis plan to the computation of treatment effect estimates will then proceed with a second, independent statistician using a blinded binary indicator of treatment to generate primary and secondary effect estimates. These estimates will be incorporated in the trial final report by the trial's writing committee while unaware of the treatment code.
Study objectives and endpoints
A CONSORT flow diagram will be generated as shown in Figure 1 .
Although the trial will be analysed as a whole, demographic, baseline, and post-baseline data, as well as primary and secondary outcomes, will also be tabulated by centre and region and/or presented graphically according to randomised treatment and summarised using descriptive statistics.
No imputation for missing data will be performed and the number of analysed observations will be reported for each summary proportion. The main primary and secondary analyses will follow a modified intention-totreat approach to define the full analysis patient set, based on all randomly assigned patients except those withdrawing consent for use of all trial data and those not fulfilling inclusion criteria and never receiving the intervention [12] .
Primary outcome
The primary outcome will be the proportion of patients with unfavourable neurological outcomes at 6 months from randomisation. This is defined from a mid-point dichotomization of the eight level ordinal Extended Glasgow Outcome Scale (GOSE) [13] , with unfavourable outcomes comprising severe disability (GOSE 2 to 4), or death (GOSE 1). The primary outcome will be modelled as a binomial random variable, with a null hypothesis of equality between EPO and placebo groups in the proportion of subjects with an unfavourable outcome. This will be assessed with an uncorrected chi-square test applied to the 2 × 2 contingency table comprising the full analysis set of patients according to randomised treatment group. This primary trial outcome will be reported as an unadjusted risk ratio with associated 95% confidence interval (CI) and also as the risk difference with 95% CI. The number needed to treat for benefit or harm will also be reported if a statistically significant difference between treatment groups is demonstrated. The odds ratio and 95% CI calculated for the primary outcome will be reported in a table of supplementary results. Sensitivity analyses of the primary and secondary outcomes will be performed using logistic regression adjusting for pre-specified baseline covariates as well as any covariate exhibiting substantial imbalance between randomisation arms, as recommended [14] . Baseline variables to be included as fixed effects when developing adjusted outcomes models comprise the following:
Secondary outcomes and pre-specified covariates
i. Geographic region (Australia combined with New Zealand, Saudi Arabia, Europe) ii. Age iii. GCS iv. Pupil reactivity v. Hypoxia vi. Hypotension vii. Marshall computerised tomography brain scan classification [15] A proportional odds cumulative logit model [16, 17] , adjusting for the same covariates, will be applied to the eight-level vector of 6-month GOSE.
A further series of exploratory secondary analyses will fit logistic models including only two covariates, namely EPO treatment and the extended IMPACT TBI probability of 6 month unfavourable outcome [18] . IMPACT extended is a composite score comprising many of the above listed baseline variables.
Adjusted estimates of the effect of EPO derived from logistic and proportional odds ordinal logistic models will be reported as adjusted risk ratios averaged over the remaining covariates, as recently recommended [19] [20] [21] . The corresponding odds ratios with 95% CIs will be reported in supplementary tables.
Log binomial regression models will be applied to return adjusted risk ratio estimates incorporating the same fixed effects covariate set as logistic models while also incorporating as a random effect the multiple levels of stratification.
Other secondary analyses also will compare treatment groups using unadjusted and adjusted logistic regression or log binomial regression as above, including assessment of outcomes according to actual treatment received (perprotocol analysis), mortality at hospital discharge and 6 months, and the proportions of adverse events including lower limb DVT or a defined composite adverse thrombotic event outcome.
Time-to-event analyses, including death, the first development of a proximal lower limb DVT or a composite thrombotic complication, will be undertaken using Kaplan-Meier curves assessed by log-rank tests, as well as unadjusted and adjusted Cox proportional hazard regression models returning hazard ratios with 95% CI.
Quality of life outcomes will be reported as means (with standard deviations) of the physical and mental health scores of the SF-12 [22] , and as the proportion of reported health problems for each domain of the EQ-5D-3 L [23] . Differences in quality of life between groups will be assessed using two-sample t tests or Wilcoxon rank-sum tests as appropriate for the SF-12 component scores, and Fisher exact or chi-squared tests for the proportions in each domain of the EQ-5D-3 L.
Cost-effectiveness will be calculated as a cost per additional patient with a favourable neurological outcome at 6 months following randomisation (defined as and the cost per additional quality-adjusted life year, with quality-adjusted life years calculated using utility scores derived from the EQ-5D-3 L conducted at 6 months postrandomisation. Costs will be determined based on resource use during the intensive care, acute and post-acute periods up to 6 months post-randomisation, and will include costs of EPO where appropriate.
Planned subgroups to assess interactions with erythropoietin therapy
Assessment for differential EPO effects across two subgroups will be obtained using interaction terms in logistic regression models. These subgroups are defined by the presence or absence of: 1) severe TBI (GCS 3 to 8); and 2) an intracranial mass lesion according to the Marshall computerised tomography scan classification (V or VI).
Data monitoring, interim analyses and statistical significance
An independent Data and Safety Monitoring Committee (DSMC) conducted oversight of the quality of the trial and had access to trial outcome and accumulated safety data, including the differential proportions of DVT and total mortality.
A group sequential statistical approach was used to perform two equally spaced interim analyses (at 33% and 66% of total recruitment) to assess the trial primary outcome. There was no provision to stop early for futility. The Haybittle-Peto criterion (|Z k | ≥ 3) for early stopping [24] was applied at these first and second interim analyses by the DSMC, and on both occasions no early stopping was necessary. Because of the negligible effect of the two interim analyses on expenditure of error (final critical value |Z 3 | ≥ 1.975 (P value 0.048), rather than 1.960), the final analyses at full recruitment will be little affected by these interim analyses and consequently all final analyses will be conducted with a Type I error alpha equal to 0.05. This level of significance will not be adjusted for multiplicity; however, the primary trial outcome is clearly defined. Unless otherwise specified, all hypothesis tests and accompanying significance levels (that is, P values) will be two-sided, with 95% CI.
Sample size and power
The trial sample size was calculated for the primary outcome using an estimated baseline 50% proportion of unfavourable neurological outcomes (death and severe disability) at 6 months from randomisation [2, 25] . Inclusion of 574 evaluable patients (two equally sized groups of 287 subjects) was estimated to provide more than 90% power to detect a 28% relative risk reduction (from 50% to 36%), and approximately 80% power to detect a 24% relative risk reduction (from 50% to 38%), in unfavourable neurological outcomes at a two-sided Type I alpha error of 0.05. A trial of this size also was estimated to have an 80% power to detect a 9% absolute risk increase in proximal lower limb DVT from an assumed baseline proportion of 18% (50% increase in relative risk) at a one-sided alpha of 0.05. The target sample size was inflated from 574 to 606 patients to allow for a combined withdrawal and loss to follow-up proportion of 5%.
Model fitting and goodness of fit assessment
Derivation of final parsimonious multivariable models and assessment of their fit to the trial data will follow standard approaches [16, 26] , including by evaluation of likelihood ratio tests to compare nested models, and otherwise each model's Akaike Information Criterion. Evaluation of model fit will include assessment of the link function and the Hosmer-Lemeshow goodness-of-fit statistic [16] .
Proportionality in ordinal logistic regression models will be assessed [27] . Also, the proportional hazards assumption across treatment arms in time-to-event analyses will be evaluated using scaled Schoenfeld residuals [28] and visual assessment of log-log plots.
Analysis software
Data capture and processing occurs initially at Monash University Clinical Informatics and Data Management Unit [11] , and these data will be exported in relevant formats for statistical analysis using current versions of SAS (SAS Institute Inc. Cary, NC, USA) and Stata (StataCorp LP, College Station, Texas, USA).
Safety and adverse event analyses
Safety and tolerability implications will be summarized using descriptive statistical methods, supplemented by calculation of CIs where appropriate. Patients with protocol deviations, adverse events and missing values will be identified, and a descriptive analysis undertaken including their relationship to treatment.
The known risk of thrombosis with EPO therapy will be specifically assessed by two secondary outcomes of this trial, and compliance with baseline and twice weekly bilateral lower limb DVT screening ultrasound examinations will be reported.
Current status
The trial commenced on 3 May 2010 at The Alfred Hospital, Melbourne Australia. Two interim analyses were conducted with approval by the DSMC to continue the trial without alteration to the research protocol. The target recruitment of 606 patients was achieved on 1 November 2014, making final 6-month outcomes available by May 2015.
Conclusions
TBI is a common and devastating condition with few proven, specific therapies available. The administration of EPO has the potential to reduce neurological damage and improve neurological outcome, and is supported by a scientific rationale and laboratory data. The EPO-TBI design aims to detect an important beneficial effect of EPO on neurological function if one exists, while minimising any thrombotic risk after TBI. Application of this statistical analysis plan to the EPO-TBI trial will facilitate unbiased evaluation of these important clinical data and support confidence in the subsequent generalization of its findings. EPO-TBI aims to provide definitive guidance for clinicians regarding the true efficacy and safety of EPO in the management of TBI.
